ArticleEquine veterinary journal2026
Evaluation of a nutraceutical for prevention of equine ulcer recurrence.
Article in Equine veterinary journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe number of horses with equine squamous gastric disease (ESGD) and equine gastric glandular disease (EGGD) recurrence when pharmacological treatment is discontinued is high.
objectiveTo examine if a commercially available nutraceutical compound containing lecithin, pectin, and meadowsweet could prevent recurrence of both ESGD and EGGD after omeprazole treatment, evaluated by repeated gastroscopic examinations and saliva biomarkers. STUDY
designBlinded, randomised, placebo-controlled clinical trial.
methodsThirty horses of mixed breeds and sex with a recent diagnosis and treatment of both ESGD and EGGD were included and randomly assigned to a placebo or a nutraceutical group. The horses received 10 mL per 100 kg bodyweight (bwt) of either nutraceutical or placebo orally for the 4-8-week duration of the study and were kept in their home environment and trained as normal. Gastroscopic grading of ESGD and EGGD and saliva were obtained at the initial diagnosis, as well as before and after the trial. Salivary biomarkers were measured by automated chemistry analysers using commercial kits. Due to the non-normal distribution of data, Friedman tests with Wilcoxon post hoc tests were applied to assess changes over time within groups, Mann-Whitney U tests were performed to evaluate difference between groups.
resultsRegardless of nutraceutical or placebo assignment, only five horses remained ulcer free after the trial. The nutraceutical was not found to be better than placebo for preventing gastric disease recurrence when evaluated by gastroscopy scores. At the time of the last gastroscopy, the nutraceutical group had lower salivary ADA and higher bicarbonate concentrations compared to the placebo group. MAIN LIMITATIONS: Salivary biomarkers need further validation.
conclusionAlthough addition of the nutraceutical did not have a significant effect in preventing ESGD or EGGD recurrence, it produced changes in salivary biomarkers suggesting a potential improvement in gastric mucosal health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.